Studies have been performed showing that a higher tumor mutation burden, a proxy marker of neoantigen formation, has a significant effect on the response rate to programmed death protein 1 and programmed death ligand 1 (PD-1/PD-L1) blockade [12,21]. Here, CD274 is linked to neoplasm.